Akademska digitalna zbirka SLovenije - logo
VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
  • Sotalol kot antiaritmik novejšega tipa = Sotalol as novel antiarrhythmic agent
    Vokač, Damijan
    Backgraund. Sotalol is a novel antiarrhythmic agent known and utilised before as a nonselective beta adrenergic blocker. Its characteristic is the combination of the beta adrenergic blockade activity ... and the ability to increase cardiac refractoriness. This dual pharmacological profile enables unpredictive antiarrhythmic potential. After oral administration the bioavailability of sotalol is stable. it is mostly eliminated in an unchanged form, by renal excretion; its half life is approximately 15 to 17 hours. Methods. Although sotalol was initially utilised for the treatment of life threatening ventricular arrhythmias, it has also been found effective in suppression of various forms of ventricular and supraventricular tachyarrhytmias. The substained monomorphic ventricular tachycardia is the most important indication among ventricular tahycardias; it is also indicated in all other nonsustained forms, with the exception of those tachycardias thatare provoked by prolonged QT interval. The most important indication in the treatment of supraventricular arrhytmias is the prevention and control of atrial fibrillation. Efficacy and safety of sotalol has been fully examined invarious clinical trials that are described in the article. The adverse effects are described and could roughly be divided into those caused by beta adrenergic blockade, and those resulting from excessive prolongation of the QTinterval. Conclusions. Sotalol is a novel antiarrhytmic drug with beta blocking and refractory period prolongation effects. It is relatively safe andeffective for the treatment of many forms of cardiac supraventricular and ventricular tachyarrhythmias. As with other drugs which prolog QT interval, the occurrence of torsade de pointes is a serious side effect. This serious side effect can, in majority of cases, be prevented by avoiding hypokalemia and limiting the doses to no more than 320 mg twice daily.
    Vir: Zdravniški vestnik : glasilo Slovenskega zdravniškega društva = Slovenian medical journal = journal of Slovenian Medical Association. - ISSN 1318-0347 (Let. 66, št. 3, 1997, str. 117-121)
    Vrsta gradiva - članek, sestavni del
    Leto - 1997
    Jezik - slovenski
    COBISS.SI-ID - 7365593

Vnos na polico